News
May 19, 2026
Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting
Sustained Therapeutics Inc. announced positive Phase 2 results for ST-01, its investigational non-opioid therapy for chronic scrotal content pain. Presented at the 2026 AUA Annual Meeting, the study showed statistically significant and durable pain reduction, supporting continued development toward Phase 3. The company believes ST-01 could offer a targeted alternative to opioids, repeat procedures, and invasive surgery.
January 8, 2026
Sustained Therapeutics Reports Positive Phase 2 Results for its Long-Acting Non-Opioid Medication for Chronic Pain
Sustained Therapeutics Inc. a clinical-stage therapeutics company developing a non-opioid treatment for pain, today announced positive results from its Phase 2 clinical trial evaluating ST-01, the Company’s novel sustained-release drug. ST-01 was designed to deliver sustained, localized non-opioid pain relief for approximately 28 days from a single injection, addressing a major unmet need for patients with limited effective long-term treatment options.
June 24, 2024
Sustained Therapeutics Announces First Patient for Cancer Trial
The first patient has entered the Phase II/III trial of ST-02, Sustained Therapeutic’s innovative cancer medication targeting Upper Tract Urethral Carcinoma (UTUC).
A rare form of cancer, UTUC affects over 7,000 individuals annually across North America. UTUC is a cancer of the inside lining of the kidney (the “collecting system” – where urine starts to drain after it is made by the kidney) and the ureter (the tube that carries urine from the kidney to the bladder).
November 16, 2023
Sustained Therapeutics announces clinical trial of second product
Sustained Therapeutics announced today regulatory clearance for a pivotal Phase II/III human trial of its second product, a novel medication for the treatment of a rare form of cancer. Upper Tract Urethral Carcinoma (“UTUC”) is an orphan disease, a malignancy of the cells lining the renal pelvis. It affects about 6,000 patients each year in North America.
November 7, 2023
Recruitment ongoing for new therapy to address painful male problem
A new clinical trial is currently recruiting men struggling with a painful, but not uncommon, condition: chronic scrotal pain. The Phase II study is testing an important new therapeutic approach to treat this condition at our centre in Vancouver and in other locations across Canada including Calgary, Winnipeg, Ottawa, Toronto and Montreal and plans to enroll 63 people over the next six months.
July 5, 2023
A successful phase 1 study of an injectable lidocaine paste for spermatic cord block in men with chronic scrotal content pain
Patients with chronic scrotal content pain (CSCP) lack effective, noninvasive
treatment options. We aimed to determine the local and systemic safety, tolerability,
pharmacokinetics (PK), and efficacy of a long-lasting local anesthetic in patients with CSCP.
March 30, 2023
Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform
A Vancouver-based therapeutics company has begun a second Phase II trial of its novel long lasting non-opioid pain medication, with a specific focus on treating Chronic Scrotal Pain (CSP), a debilitating condition estimated to affect 1% of the male population. Sustained Therapeutics’ first sustained release drug candidate, ST-01, is designed to slowly release over about 28 days from a single injection.
January 5, 2023
Sustained Therapeutics Advancing Clinical Trials for Novel Drug Delivery Platform
A Vancouver-based therapeutics company has received regulatory approval to begin the second Phase II trial of its novel long lasting non-opioid pain medication. Sustained Therapeutics is evaluating a sustained release platform technology that could revolutionize how we treat pain and significantly improve the lives of individuals living with chronic pain.
